NCT07424404: A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- State
- Under way
- Phase
- Phase 3
- People
- 400 planned
- Started
- 7 Apr 2026
- Primary completion
- 8 Mar 2030
- Arms
- Administration of KarXT + KarX-EC for Autism Spectrum Disorder
- Results
- None posted
- 20 Feb 2026: Trial registered
- 7 Apr 2026: Trial started